Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.75 Contact Hours.
Acknowledgment of Support
This activity is supported by an educational grant from Bayer Healthcare Pharmaceuticals Inc.
Virtual Case Studies™ in Chronic Kidney Disease: Optimizing Patient Selection When Considering Non-Steroidal Mineralocorticoid Receptor Antagonists
Release Date: September 30, 2021
Expiration Date: September 30, 2022
Chronic kidney disease (CKD) is a disease multiplier that increases the risk of stroke and other cardiovascular diseases. Patients with CKD and diabetes have a high risk of complications, including diabetic retinopathy, diabetic foot, anemia, metabolic bone disease, fracture, infection, and neuropathy. Patients given a diagnosis of CKD also have a greater risk of iatrogenic injury from drug therapy, including acute kidney injury, hypoglycemia, and hyperkalemia. Affected patients also have high rates of comorbidities, such as depression and heart failure. Not surprisingly, this burden of complications and comorbidity translates to poor quality of life and substantially higher use of health care resources and associated costs.
This online activity is designed to promote clinical decision-making via virtual case simulations and expert faculty commentary. Clinicians are presented with 2 patient case simulations; each is followed by a panel discussion that addresses main clinical points related to the simulations. In addition, members of the faculty discuss strategies for renal and cardiovascular protection and the importance of multidisciplinary care for patients with CKD.
Acknowledgement of Commercial Support
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This program is intended for Nephrologists, Primary Care Physicians, Endocrinologists, Cardiologists, and Physician Assistants/Nurse Practitioners.
Upon successful completion of this activity, you should be better prepared to:
- Incorporate guideline recommended criteria/testing procedures for the diagnosis of DKD
- Analyze the role of pathophysiologic mechanism of DKD in the progression of cardiorenal dysfunction
- Develop individualized treatment plans incorporating non-glucose lowering therapies for patients with DKD
- Identify patient risk factors for developing hyperkalemia with non-glucose lowering therapies
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities
Professor of Medicine
Director, American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Disclosures: Consultant: Merck, Bayer, Vascular Dynamics, KBP Biosciences, Ionis Pharmaceuticals, Alnylam Pharmaceuticals, AstraZeneca, Quantum Genomics, Horizon Therapeutics, Novo Nordisk.
Kidney & Hypertension Associates
Disclosures: Speakers’ Bureau: Bayer Pharmaceuticals.
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Disclosures: Biff F. Palmer, MD, has no relevant financial relationships with ineligible companies.
Adjunct Professor of Epidemiology and Biostats
Case Western University
Population & Quantitative Health Sciences
Clinical Professor of Medicine
Central Michigan University College of Medicine
Mount Pleasant, MI
Disclosures: Other Support: Advisory Board: Vifor Pharma, DIAMOND trial.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.